Method for producing an ellagic acid-containing composition and ellagic acid-containing composition

Abstract

To provide a method for producing a new ellagic acid-containing composition capable of improving the solubility of ellagic acid.SOLUTION: The present embodiment is a method for producing an ellagic acid-containing composition, the method involving: a step for preparing a solution containing at least an aqueous medium and a raw material derived from a plant of the genus Terminalia and including ellagic acid; and a step for subjecting the solution to heating treatment.SELECTED DRAWING: None

Description

Technical Field

[0001] The present disclosure relates to a method for producing an ellagic acid-containing composition and an ellagic acid-containing composition.

Background Art

[0002] Ellagic acid is a promising natural compound for which various effects such as anti-cancer action, anti-inflammation, anti-oxidation, anti-obesity, and whitening effects have been reported.

[0003] For example, in Patent Document 1, it is described that ellagic acid has excellent physiological activities such as an antioxidant action on edible oils and fats, an antimutagenic action on microorganisms, and an antitumor action on small animals such as mice and rats, and is a useful compound in the food and pharmaceutical industries.

[0004] However, ellagic acid has low solubility in water and is difficult to use in aqueous products. Therefore, studies have been conducted to improve the solubility of ellagic acid.

[0005] For example, in Patent Document 2, a method for producing an ellagic acid composition is disclosed, which includes a step of mixing a raw material containing a guava leaf extract and containing 1 to 5% by mass of free ellagic acid in solid content with an aqueous medium to prepare a heat-treated raw material, and a step of heat-treating the heat-treated raw material at 100 to 180°C.

Prior Art Documents

Patent Documents

[0006]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0007] However, the method described in Patent Document 2 is limited to raw materials containing guava leaf extract and containing 1 to 5% by mass of free ellagic acid in the solid content. Furthermore, the method described in Patent Document 2 requires heating at a high temperature of 100 to 180°C. Therefore, there is a need for a new method for producing an ellagic acid-containing composition that can improve the solubility of ellagic acid.

[0008] Therefore, this disclosure has been made in view of at least one of the above problems, and the object of this disclosure is to provide a new method for producing an ellagic acid-containing composition that can improve the solubility of ellagic acid. [Means for solving the problem]

[0009] Examples of embodiments of this model are as follows.

[0010] (1) A step of preparing a solution containing at least an ellagic acid-containing raw material derived from a plant of the genus Terminalia catappa and an aqueous medium, and The process of subjecting the aforementioned solution to heat treatment. A method for producing an ellagic acid-containing composition. (2) The manufacturing method according to (1), further comprising a step of hydrolyzing the ellagitannin contained in the raw material to produce further ellagic acid, and then heating the solution obtained by the hydrolysis treatment. (3) The manufacturing method according to (2), wherein the hydrolysis treatment is hydrolysis by acid. (4) The method of production according to any one of (1) to (3), wherein the solution further contains ellagic acid added separately from the ellagic acid contained in the raw material derived from the genus Terminalia catappa. (5) The manufacturing method described in any one of (1) to (4), wherein the plant of the genus Terminalia is Terminalia catappa. (6) The method for producing a product according to any one of (1) to (5), wherein the raw material derived from a plant of the genus Terminalia is at least one material selected from the leaves, fruits, stems, and branches of a plant of the genus Terminalia, or an extract obtained by extracting from at least one material selected from the leaves, fruits, stems, and branches of a plant of the genus Terminalia using an extraction medium. (7) The method for producing a raw material derived from a plant of the genus Terminalia catappa, wherein the raw material is an extract obtained by extracting from at least one material selected from the leaves, fruits, stems, and branches of a plant of the genus Terminalia catappa using an extraction medium. (8) The manufacturing method according to (6) or (7), wherein the extraction medium is water, an aqueous medium, or a mixed solvent thereof. (9) The manufacturing method according to any one of (6) to (8), wherein the extraction medium is water, alcohol, or a mixed solvent of water and alcohol. (10) The manufacturing method according to any one of (1) to (9), wherein the heat treatment temperature is 60°C or higher. (11) The manufacturing method according to any one of (1) to (10), wherein the heat treatment temperature is less than 100°C. (12) The method of production according to any one of (1) to (11), wherein the aqueous medium in the solution is water, alcohol, or a mixed solvent of water and alcohol. (13) A manufacturing method according to any one of (1) to (12), further comprising a step of concentrating the solution after the step of applying heat treatment. (14) The manufacturing method according to any one of (1) to (13), wherein the concentration of ellagic acid dissolved in the solution obtained by the step of heat treatment or, if applicable, the step of concentration treatment, is 50 μg / mL or more. (15) A manufacturing method according to any one of (1) to (14), further comprising the step of drying the solution after the step of applying heat treatment, or after the step of applying concentration treatment if applicable, to obtain an ellagic acid-containing solid. (16) An ellagic acid-containing composition obtained by the manufacturing method described in any one of (1) to (15). (17) Pharmaceuticals, cosmetics, quasi-drugs, or food and beverages containing the ellagic acid composition described in (16). (18) Use of raw materials derived from plants of the genus Terminalia catappa to solubilize ellagic acid, A solution containing raw materials derived from Terminalia catappa plants and an aqueous medium is heated in the presence of ellagic acid and used. [Effects of the Invention]

[0011] This disclosure provides a method for producing a novel ellagic acid-containing composition that can improve the solubility of ellagic acid. [Modes for carrying out the invention]

[0012] This embodiment is a method for producing an ellagic acid-containing composition, comprising the steps of preparing a solution containing at least an ellagic acid-containing raw material derived from a plant of the genus Terminalia catappa and an aqueous medium, and subjecting the solution to a heat treatment.

[0013] This embodiment provides a method for producing a novel ellagic acid-containing composition that can improve the solubility of ellagic acid. The inventors have discovered that by heating a solution containing a raw material derived from a plant of the genus Terminalia catappa and an aqueous medium in the presence of ellagic acid, the effect of solubilizing ellagic acid can be obtained, leading to this embodiment. The reason why the ellagic acid solubilizing effect is obtained by heating a solution containing a raw material derived from a plant of the genus Terminalia catappa and ellagic acid is presumed to be that components contained in the raw material act on the ellagic acid through the heat treatment, causing it to solubilize. It is presumed that the components contained in the raw material act on the ellagic acid through the formation of inclusion complexes, salt formation, or association formation, etc. However, this presumption does not limit this embodiment.

[0014] The manufacturing method according to this embodiment will be described in detail below.

[0015] This embodiment includes a step of preparing a solution containing at least an ellagic acid-containing raw material derived from a plant of the genus Terminalia catappa and an aqueous medium.

[0016] The form of preparing the solution is not particularly limited. For example, it includes a form of preparing the solution by mixing at least a raw material derived from a plant of the genus Terminalia and an aqueous medium, a form of preparing the solution by purchasing the solution, and the like.

[0017] Plants of the genus Terminalia are trees containing a high content of ellagic acid. In the present embodiment, the plant of the genus Terminalia is preferably Terminalia catappa from the viewpoint of containing a high content of ellagic acid.

[0018] In this specification, ellagic acid is used in the sense of including free ellagic acid, its salts, and solvates (including hydrates). Although there are many ellagitannins having a structure in which ellagic acid is bound to sugar in plants of the genus Terminalia, in this specification, ellagic acid and ellagitannin are used separately.

[0019] The raw material derived from a plant of the genus Terminalia is not particularly limited. For example, it includes at least one material selected from leaves, fruits, trunks, and branches of plants of the genus Terminalia, and extracts extracted from at least one material selected from leaves, fruits, trunks, and branches of plants of the genus Terminalia by an extraction medium. As at least one material selected from leaves, fruits, trunks, and branches, for example, cut products, crushed products, ground products, pulverized products, etc. can be used. The materials may be used alone or in combination of two or more.

[0020] The extract derived from a plant of the genus Terminalia can be prepared by extracting the contained components from at least one material selected from leaves, fruits, trunks, and branches with an extraction medium (for example, an aqueous medium such as water or ethanol). As the raw material derived from a plant of the genus Terminalia, it is preferable to use an extract, and particularly, an extract extracted using water, an aqueous medium, or a mixed solvent thereof as the extraction medium is preferable. The extract derived from a plant of the genus Terminalia contains a high content of ellagic acid derived from a plant of the genus Terminalia.

[0021] The extract derived from the genus Terminalia catappa is preferably a leaf extract of Terminalia catappa. Terminalia catappa leaves are a material that contains a high content of ellagic acid derived from Terminalia catappa. The Terminalia catappa leaf extract is preferably extracted using water, an aqueous medium, or a mixture thereof as the extraction medium.

[0022] The extraction method is not particularly limited and includes, for example, ultrasonic extraction, microwave extraction, solid-liquid extraction, liquid-liquid extraction, immersion extraction, decoction extraction, leaching extraction, steam distillation extraction, reflux extraction, and agitation extraction. The extraction method may also be heated extraction, room temperature extraction, or cold extraction. The extraction temperature is not particularly limited, but from the viewpoint of increasing extraction efficiency, it is preferably 0°C or higher, and preferably 20°C or higher. The extraction temperature is also, for example, 100°C or lower.

[0023] The extraction medium is not particularly limited and can be, for example, water (including water vapor) or aqueous media such as alcohol, subcritical or supercritical carbon dioxide, or edible oils and fats such as soybean oil, rapeseed oil, sunflower oil, palm oil, or lard. Among these, it is preferable to use water, aqueous media, or a mixture thereof as the extraction medium. Examples of alcohols used as aqueous media include ethanol or propanol. As an extraction medium, for example, an aqueous solution of ethanol at 30-70 v / v% can also be used. Alternatively, a solvent obtained by adding an acid or alkali to the above extraction solvent to adjust the pH may be used. The extraction medium may be used alone or in combination of two or more types.

[0024] The extract may be used as is, but may be purified, concentrated (e.g., vacuum concentration, membrane concentration), diluted, or filtered as needed. Furthermore, the extracted solution may be dried by spray drying, freeze-drying, or concentrated to dryness and used as a dried product. For example, the extract can be prepared as an extract containing the extraction medium, or as a solid (e.g., freeze-dried or spray-dried) product from which the extraction medium has been removed.

[0025] The ellagic acid content in the extract is preferably 2% or more, preferably 5% or more, and preferably 10% or more, based on dry weight. Furthermore, the ellagic acid content in the extract is preferably 25% or less, preferably 20% or less, and preferably 15% or less, based on dry weight.

[0026] The aqueous medium is water, an organic solvent that mixes uniformly with water, or a mixture thereof. Examples of water include tap water, distilled water, deionized water, and purified water. The water may contain solutes such as salts, sugars, and pH adjusters. The organic solvent is not particularly limited as long as it mixes uniformly with water, but examples include alcohols. Examples of alcohols include monohydric alcohols such as ethanol or propanol, dihydric alcohols such as propylene glycol or butylene glycol, and trihydric alcohols such as glycerin. As the aqueous medium, for example, a 30-70 v / v% aqueous solution of ethanol can be used. The aqueous medium may be used alone or in combination of two or more types.

[0027] One aspect of this embodiment may further include a step of hydrolysis to hydrolyze the ellagitannin contained in the raw material to produce further ellagic acid. In this case, the solution subjected to the hydrolysis treatment is subjected to the heat treatment described later. By hydrolyzing the ellagitannin contained in the raw material, the concentration of ellagic acid in the solution can be further increased.

[0028] The hydrolysis treatment described above is not particularly limited as long as it can hydrolyze the ellagitannin contained in the raw material to produce further ellagic acid, but examples include hydrolysis by acid or hydrolysis by enzyme. This hydrolysis may be further accelerated by the heat treatment described later.

[0029] Regarding hydrolysis by acid, the acid is added to hydrolyze the ellagitannin contained in the raw material to produce ellagic acid. Furthermore, this hydrolysis by acid may be further accelerated by the heat treatment described later.

[0030] The acid is not particularly limited, but examples include hydrochloric acid or sulfuric acid. The acid may be used alone or in combination of two or more types.

[0031] In the case of hydrolysis by acid, the pH of the solution (at 20°C) is not particularly limited as long as the hydrolysis reaction occurs, but for example, it is 5 or less. From the viewpoint of efficiently causing the hydrolysis reaction of ellagitannin, the pH of the solution (at 20°C) is preferably 4 or less, preferably 3 or less, preferably 2 or less, and preferably 1 or less.

[0032] Regarding enzymatic hydrolysis, the enzyme used for hydrolysis is not particularly limited as long as it can hydrolyze ellagitannin to produce ellagic acid, but tannase can be given as an example. Tannase can be isolated or prepared from fungal or bacterial sources, for example. Examples of tannase include tannase obtained by culturing tannase-producing bacteria of the genera Aspergillus, Penicillium, and Rhizopus. Among these, tannase derived from Aspergillus oryzae is preferred. The concentration of tannase in the solution is not particularly limited, but for example, it is 10 Unit / L to 500 Unit / L, and preferably 20 Unit / L to 150 Unit / L.

[0033] In one embodiment of this embodiment, the solution may further contain ellagic acid added separately from the ellagic acid contained in the raw material derived from the genus Terminalia catappa. One aspect of this embodiment may include a step of further adding ellagic acid to the solution separately from the ellagic acid contained in the raw material, thereby obtaining an ellagic acid-containing composition having a higher ellagic acid concentration.

[0034] Regarding the amount of ellagic acid added to the solution, from the viewpoint of increasing the ellagic acid concentration in the resulting ellagic acid-containing composition, it is preferable to add ellagic acid so that the ellagic acid content in the solution after addition is preferably 5% by mass or more, preferably 6% by mass or more, preferably 7% by mass or more, preferably 8% by mass or more, preferably 9% by mass or more, and preferably 10% by mass or more, based on solid content. Furthermore, regarding the amount of ellagic acid added to the solution, it is preferable to add ellagic acid so that the ellagic acid content in the solution after addition is preferably 20% by mass or less, preferably 19% by mass or less, preferably 18% by mass or less, preferably 17% by mass or less, preferably 16% by mass or less, and preferably 15% by mass or less, based on solid content.

[0035] The addition of ellagic acid may be carried out by adding a compound consisting of ellagic acid itself (including free ellagic acid, its salts, and solvates), or by adding a material containing ellagic acid (for example, an extract from a plant). For example, ellagic acid is commercially available from Fujifilm Wako Pure Chemical Industries, Ltd., and ellagic acid dihydrate is commercially available from Tokyo Chemical Industries, Ltd. As for materials containing ellagic acid, for example, pomegranate ellagic acid is commercially available from Sabinsa Japan Corporation.

[0036] The method of performing hydrolysis and the method of further adding ellagic acid may be combined as appropriate. As a result, the resulting ellagic acid-containing composition can contain ellagic acid contained in the raw materials, ellagic acid produced by the hydrolysis reaction of ellagitannin, and ellagic acid added separately from the ellagic acid contained in the raw materials derived from the genus Terminalia catappa, and may have a higher ellagic acid concentration.

[0037] The content of raw materials (especially extracts) derived from Terminalia catappa plants in the solution is preferably 60% by mass or more, preferably 70% by mass or more, and preferably 80% by mass or more, based on solid content, in order to improve the solubility of ellagic acid. Furthermore, the content of raw materials (especially extracts) derived from Terminalia catappa plants in the solution is preferably 100% by mass or less, preferably less than 100% by mass, and preferably 99% by mass or less. In this specification, the solid content of raw materials derived from Terminalia catappa plants refers to the dry mass if the raw material is in solid form, and if it is in a form other than solid (e.g., liquid or paste), it refers to the mass after drying the raw material in an electric constant-temperature dryer at 105°C for 3 hours to remove volatile components.

[0038] The total solid content in the solution is not particularly limited, but for example, it should be 0.5 g / L or more and 50 g / L or less.

[0039] The solution may contain other components in addition to the components mentioned above. These other components can be added in an amount that does not interfere with the effects of this embodiment, and the content of these other components in the solution is, for example, 20% by mass or less, preferably 15% by mass or less, preferably 10% by mass or less, preferably 5% by mass or less, and preferably 1% by mass or less. Examples of these other components include the organic solvent in the ellagic acid-containing solution used to incorporate a predetermined amount of ellagic acid into the solution.

[0040] This embodiment includes a step of subjecting the above solution to heat treatment.

[0041] As described above, the heat treatment provides an ellagic acid solubilization effect. This is presumed to be because components contained in the raw materials act on ellagic acid through the formation of inclusion complexes, salts, or associations during the heat treatment, thereby solubilizing the ellagic acid. However, this presumption does not limit this embodiment.

[0042] The heat treatment temperature is preferably 60°C or higher, preferably 65°C or higher, preferably 70°C or higher, preferably 75°C or higher, and preferably 80°C or higher, from the viewpoint of improving the solubility of ellagic acid. Furthermore, from the viewpoint of the thermal stability of the components, the heat treatment temperature is preferably 180°C or lower, preferably 170°C or lower, and preferably 160°C or lower. Moreover, from the viewpoint of energy cost, the heat treatment temperature is preferably less than 100°C, preferably 99°C or lower, and preferably 98°C or lower. This embodiment is particularly excellent in that an excellent ellagic acid solubilization effect can be obtained even when the heat treatment temperature is below 100°C. The heat treatment time may vary depending on the treatment method and temperature, but for example, it is 10 minutes to 10 hours. These temperature and time conditions are merely examples and can be set appropriately considering the interrelationship of temperature and time and other factors. The enzyme used in the hydrolysis treatment can also be deactivated in the heat treatment.

[0043] The heat treatment method is not particularly limited, and known methods can be applied. Heating can be carried out under atmospheric pressure or under pressurized pressure. Heat treatment may also be carried out by steam heating, and continuous or batch type steamers or autoclaves may be used.

[0044] The heat-treated solution may be cooled as appropriate. The temperature of the solution after cooling is preferably 50°C or lower, and more preferably 30°C or lower. The cooling method is not particularly limited and can be, for example, by cooling with a condenser or by leaving it at room temperature.

[0045] The ellagic acid concentration in the solution obtained after heat treatment is preferably 50 μg / mL or higher, preferably 60 μg / mL or higher, preferably 70 μg / mL or higher, preferably 80 μg / mL or higher, preferably 90 μg / mL or higher, and preferably 100 μg / mL or higher.

[0046] In the above, the steps of preparing the solution, performing hydrolysis, and performing heat treatment have been indicated as at least the steps of this embodiment, but the order in which they are performed is not particularly limited as long as it does not hinder the effects of this embodiment. For example, this embodiment basically assumes that the steps of preparing the solution, performing hydrolysis, and performing heat treatment are performed separately, but it is not necessarily required that they be performed separately in that order. For example, this embodiment may also include cases in which the steps of preparing the solution and performing heat treatment are performed simultaneously. As a specific example, raw materials derived from Terminalia catappa plants may be added while heating the aqueous medium. Also, for example, this embodiment may also include cases in which the steps of preparing the solution and performing hydrolysis are performed simultaneously. As a specific example, raw materials derived from Terminalia catappa plants may be added to a liquid containing an aqueous medium and an acid or enzyme. Also, for example, this embodiment may also include cases in which the steps of performing hydrolysis and performing heat treatment are performed simultaneously. As a specific example, an acid or enzyme may be added while heating the solution. Furthermore, this embodiment may also include cases where the steps of preparing the solution, performing hydrolysis, and performing heat treatment are carried out simultaneously. Specifically, raw materials derived from Terminalia catappa plants may be added while heating an aqueous medium, an acid, or a liquid containing an enzyme. Moreover, although the above describes a form in which the solution may further contain ellagic acid added separately from the ellagic acid contained in the raw materials derived from Terminalia catappa plants, the separately added ellagic acid may be contained in the solution during the solution preparation step, in the solution during the hydrolysis treatment step, or in the solution during the heat treatment step, and is not particularly limited as long as the separately added ellagic acid is present in the solution during the heat treatment.

[0047] The resulting solution can be subjected to purification, concentration, or drying treatments as needed to obtain an ellagic acid-containing composition.

[0048] This embodiment may include a purification step of removing any undissolved solids from the heat-treated solution. The removal method is not particularly limited, but examples include centrifugation, decantation, or filtration.

[0049] This embodiment may include a step of concentrating the heat-treated solution as a concentration process. The ellagic acid-containing composition may be in the form of a solution or a paste. Examples of methods for concentrating the solution include general methods such as vacuum concentration (e.g., vacuum centrifugation) or membrane concentration.

[0050] The ellagic acid concentration of the ellagic acid-containing composition after concentration treatment may be, for example, 500 μg / mL or more. Preferably, the ellagic acid concentration of the ellagic acid-containing composition after concentration treatment is 750 μg / mL or more, preferably 800 μg / mL or more, preferably 850 μg / mL or more, preferably 900 μg / mL or more, and preferably 950 μg / mL or more. Due to the ellagic acid solubilizing effect, the ellagic acid-containing composition obtained in this embodiment does not precipitate ellagic acid even after concentration, and ellagic acid may exist in a dissolved state.

[0051] This embodiment may include a drying step in which the solution is subjected to a drying treatment to obtain an ellagic acid-containing solid. The ellagic acid-containing composition may be in the form of a solid such as a powder or granules. Examples of methods for removing the medium include freeze-drying, evaporation to dryness, or spray drying. The drying step may be performed after the concentration treatment. The obtained solid may be subjected to classification, granulation, grinding, etc., as necessary.

[0052] The ellagic acid-containing composition according to this embodiment, obtained as a solid, exhibits excellent solubility of ellagic acid in water, even when added to water again. This indicates that, even when the ellagic acid-containing composition according to this embodiment is in solid form, ellagic acid is present in the solid in a form that is easily solubilized.

[0053] One aspect of this embodiment may be an ellagic acid-containing composition obtained by the manufacturing method according to this embodiment. Another aspect of this embodiment may be a pharmaceutical, cosmetic, quasi-drug, or food or beverage containing the ellagic acid-containing composition. In this embodiment, "food or beverage" is used to mean not only general food or beverages, but also foods other than pharmaceuticals and quasi-drugs that can be consumed for the purpose of maintaining or promoting health (e.g., health foods, functional foods, health functional foods, or foods for special dietary uses). Health foods include foods provided under names such as nutritional supplements, health supplements, and supplements. Health functional foods are defined by the Food Sanitation Act or the Food Promotion Act and include Foods for Specified Health Uses and Foods with Nutrient Function Claims, which can display specific health effects, functions of nutritional components, reduction of disease risk, etc. The form of food or beverage may be any form suitable for consumption, such as solid, liquid, granular, granular, powder, capsule, cream, or paste. [Examples]

[0054] The embodiment will be described below with reference to examples. Note that the specific aspects of this embodiment are not limited to those shown in the examples, and the configuration can be modified as appropriate without impairing the spirit of this disclosure.

[0055] [Measurement method] (Ellagic acid concentration) Quantitative analysis of free ellagic acid was performed using a Thermo SCIENTIFIC liquid chromatograph and a Waters ACQUITY column. TM A PREMIER HSS T3 (2.1 x 100 mm) column was used, and the gradient method was performed at a column temperature of 40°C. Mobile phase A was a 0.05% aqueous acetic acid solution, and mobile phase B was acetonitrile containing 0.05% acetic acid, delivered at 250 μL / min. The gradient conditions were as follows.

[0056] [Table 1]

[0057] The sample injection volume was 2 μL, and quantification was performed by measuring the absorbance at a wavelength of 252 nm.

[0058] (pH) The pH was measured using a pH meter (SPH70, ASONE) after the sample temperature was brought to 20°C.

[0059] (Preparation Example 1: 50% Ethanol Extract) As a plant of the genus Terminalia catappa, pulverized leaves of Terminalia catappa (collected from Henza Island (Yonashiro Henza, Uruma City, Okinawa Prefecture)) were used. A dispersion was prepared by adding 5 mL of 50% ethanol aqueous solution to 100 mg of pulverized Terminalia catappa leaves. Next, the dispersion was subjected to sonication for 1 hour. Then, the dispersion after sonication was filtered to obtain an extract. The extract was then concentrated using a vacuum centrifuge, followed by freeze-drying to obtain a freeze-dried product. This freeze-dried product was used as the extract derived from Terminalia catappa plants. In the experiments described below, an extract-containing solution (10 mg / mL) prepared by dissolving and dispersing the freeze-dried product in a 50% ethanol aqueous solution to a concentration of 10 mg / mL was used.

[0060] (Preparation example 2: water extract) As a plant of the genus Terminalia catappa, pulverized leaves of Terminalia catappa (collected from Henza Island (Yonashiro Henza, Uruma City, Okinawa Prefecture)) were used. A dispersion was prepared by adding 5 mL of pure water to 100 mg of pulverized Terminalia catappa leaves. Next, the dispersion was subjected to sonication for 1 hour. Then, the dispersion after sonication was filtered to obtain an extract. The extract was then concentrated using a vacuum centrifuge, followed by freeze-drying to obtain a freeze-dried product. This freeze-dried product was used as the extract derived from Terminalia catappa plants. When used in the following experiments, an extract-containing solution (10 mg / mL) prepared by dissolving and dispersing the freeze-dried product in pure water to a concentration of 10 mg / mL was used.

[0061] (Preparation Example 3: 100% Ethanol Extract) As a plant of the genus Terminalia catappa, pulverized leaves of Terminalia catappa (collected from Henza Island (Yonashiro Henza, Uruma City, Okinawa Prefecture)) were used. A dispersion was prepared by adding 5 mL of 100% ethanol to 100 mg of pulverized Terminalia catappa leaves. Next, the dispersion was subjected to sonication for 1 hour. Then, the dispersion after sonication was filtered to obtain an extract. The extract was then concentrated using a vacuum centrifuge, followed by freeze-drying to obtain a freeze-dried product. This freeze-dried product was used as the extract derived from Terminalia catappa plants. When used in the following experiments, an extract-containing solution (10 mg / mL) prepared by dissolving and dispersing the freeze-dried product in a 100% ethanol aqueous solution to a concentration of 10 mg / mL was used.

[0062] (Preparation example 4: Ellagic acid-containing liquid) Ellagic acid used was manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. (Cat. No. 057-08751). For use in the experiment, an ellagic acid-containing solution (1 mg / mL) was prepared by dissolving ellagic acid in pyridine to a concentration of 1 mg / mL.

[0063] [Investigation into increasing ellagic acid concentration through hydrolysis] (Example 1) A solution was prepared in a 1.5 mL tube by mixing 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 (corresponding to 500 μg of extract) with 50 μL of pyridine. The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare an extract-containing powder. Next, 500 μL of hydrochloric acid (2N) was added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Next, the tube containing the mixed solution was placed in a block incubator and incubated at 95°C for 4 hours to perform hydrolysis. Next, the incubated mixed solution was left in the ambient environment to return to room temperature (23°C). After that, the mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition E1.

[0064] (Comparative Example 1) A solution was prepared in a 1.5 mL tube by mixing 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 (corresponding to 500 μg of extract) with 50 μL of pyridine. The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare an extract-containing powder. Next, 500 μL of pure water was added to the tube and mixed to prepare a mixed solution. The mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition C1.

[0065] (Comparative Example 2) Liquid composition C2 was obtained in the same manner as in Comparative Example 1, except that DMSO was added instead of pure water.

[0066] (Comparative Example 3) A 1.5 mL solution was prepared in a tube by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 (corresponding to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution. The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare ellagic acid-containing powder. Next, 500 μL of hydrochloric acid (2N) was added to the tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. Next, the tube containing the mixed solution was placed in a block incubator and incubated at 95°C for 4 hours. Next, the incubated mixed solution was left in the ambient environment to return to room temperature (23°C). After that, the mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition C3.

[0067] (Comparative Example 4) A solution was prepared in a 1.5 mL tube by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 (corresponding to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution. The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare ellagic acid-containing powder. Next, 500 μL of pure water was added to the tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. The mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition C4.

[0068] (Comparative Example 5) Liquid composition C5 was obtained in the same manner as in Comparative Example 4, except that DMSO was added instead of pure water.

[0069] (evaluation) The ellagic acid concentration of the obtained liquid composition was measured according to the measurement method described above. The results are shown in Table 2.

[0070] [Table 2]

[0071] (Consideration) The liquid composition E1 obtained in Example 1 was prepared by adding hydrochloric acid to an extract derived from a plant of the genus Terminalia catappa, and then subjecting the resulting mixed solution to hydrolysis by heating. The ellagic acid concentration in the solution obtained after hydrolysis was 114.5 μg / mL, indicating that it was dissolved in the solution at a high concentration. Since the solubility of ellagic acid in water is approximately 20 μg / mL, it can be seen that in Example 1, ellagic acid was solubilized to a level far exceeding its solubility. In Example 1, the extract-containing solution (10 mg / mL) was mixed with pyridine, and then the solvent was removed by centrifugation under reduced pressure. However, this mixing operation with pyridine was performed in relation to the experimental examples described later, from the perspective of conditions, etc., and is an operation that can be omitted in this embodiment.

[0072] Regarding Comparative Example 1, the ellagic acid concentration of liquid composition E1 in Example 1 was 114.5 μg / mL, while the ellagic acid concentration of liquid composition C1 in Comparative Example 1 was 27.6 μg / mL. This is thought to be because, in Example 1, hydrolysis treatment of the extract derived from Terminalia catappa plants by heating in the presence of hydrochloric acid hydrolyzed the ellagitannins contained in the extract, producing ellagic acid, and the resulting ellagic acid was solubilized beyond its saturation concentration in water by the action of components contained in the extract derived from Terminalia catappa.

[0073] Regarding Comparative Example 2, since DMSO, which has excellent solubility for ellagic acid, was used as the solvent in Comparative Example 2, the ellagic acid concentration in liquid composition C2 of Comparative Example 2 is considered to represent the amount of ellagic acid originally contained in the extract. The ellagic acid concentration in liquid composition E1 of Example 1 was 114.5 μg / mL, while the ellagic acid concentration in liquid composition C2 of Comparative Example 2, which represents the amount of ellagic acid originally contained in the extract, was 27.7 μg / mL. This is thought to be because, in Example 1, ellagitannin contained in the extract was hydrolyzed to produce ellagic acid.

[0074] The liquid composition C3 of Comparative Example 3 was obtained by adding hydrochloric acid to an ellagic acid-containing solution (without extract from Terminalia catappa plants) and heating it. However, this demonstrates that a high-concentration ellagic acid-containing composition cannot be obtained by simply heating in hydrochloric acid without extract from Terminalia catappa plants. Comparative Examples 4 and 5 are shown as controls for the use of pure water or DMSO, but Example 1 achieved a high ellagic acid concentration comparable to that of the liquid composition C5 of Comparative Example 5, which used DMSO.

[0075] [Investigation into improving the solubility of ellagic acid 1] (Example A1) A 1.5 mL solution was prepared in a tube by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 (corresponding to 50 μg of ellagic acid) with 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 (corresponding to 500 μg of extract). The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare an ellagic acid + extract-containing powder. Next, 500 μL of pure water was added to the tube and mixed with the ellagic acid + extract-containing powder to prepare a mixed solution. Next, the tube containing the mixed solution was placed in a block incubator and incubated at 95°C for 20 minutes. Next, the incubated mixed solution was left in the ambient environment to return to room temperature (23°C). After that, the mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition E-A1.

[0076] (Example A2) Liquid composition E-A2 was obtained in the same manner as in Example A1, except that the heating temperature in the block incubator was changed to 75°C.

[0077] (Example A3) Liquid composition E-A3 was obtained in the same manner as in Example A1, except that heating was performed at 121°C using an autoclave instead of heating in a block incubator.

[0078] (Example A4) Liquid composition E-A4 was obtained in the same manner as in Example A1, except that the heating temperature in the block incubator was changed to 55°C.

[0079] (Comparative Example A1) Liquid composition C-A1 was obtained in the same manner as in Example A1, except that it was left at room temperature (23°C) for 20 minutes without heating in a block incubator.

[0080] (Example B1) A solution was prepared in a 1.5 mL tube by mixing 50 μL of pyridine (without ellagic acid) with 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 (corresponding to 500 μg of extract). The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare an extract-containing powder. Next, 500 μL of pure water was added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Next, the tube containing the mixed solution was placed in a block incubator and incubated at 95°C for 20 minutes. Next, the incubated mixed solution was left in the ambient environment to return to room temperature (23°C). After that, the mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition E-B1.

[0081] (Example B2) Liquid composition E-B2 was obtained in the same manner as in Example B1, except that the heating temperature in the block incubator was changed to 75°C.

[0082] (Example B3) Liquid composition E-B3 was obtained in the same manner as in Example B1, except that heating was performed at 121°C using an autoclave instead of heating in a block incubator.

[0083] (Example B4) Liquid composition E-B4 was obtained in the same manner as in Example B1, except that the heating temperature in the block incubator was changed to 55°C.

[0084] (Comparative Example B1) Liquid composition C-B1 was obtained in the same manner as in Example B1, except that it was left at room temperature (23°C) for 20 minutes without heating in a block incubator.

[0085] (Comparative example B2) A solution was prepared in a 1.5 mL tube by mixing 50 μL of pyridine (without ellagic acid) with 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 (corresponding to 500 μg of extract). The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare an extract-containing powder. Next, 500 μL of DMSO was added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Then, the mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition C-B2.

[0086] (Comparative Example C1) A 1.5 mL solution was prepared in a tube by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 (corresponding to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution (without the addition of extract). The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare ellagic acid-containing powder. Next, 500 μL of pure water was added to the tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. Next, the tube containing the mixed solution was placed in a block incubator and incubated at 95°C for 20 minutes. Next, the incubated mixed solution was left in the ambient environment to return to room temperature (23°C). After that, the mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition C-C1.

[0087] (Comparative Example C2) Liquid compositions C-C2 were obtained in the same manner as in Comparative Example C1, except that the heating temperature in the block incubator was changed to 75°C.

[0088] (Comparative Example C3) Liquid compositions C-C3 were obtained in the same manner as in Comparative Example C1, except that heating was performed at 121°C using an autoclave instead of a block incubator.

[0089] (Comparative example C4) Liquid compositions C-C4 were obtained in the same manner as in Comparative Example C1, except that the heating temperature in the block incubator was changed to 55°C.

[0090] (Comparative example C5) Liquid compositions C-C5 were obtained in the same manner as in Comparative Example C1, except that they were left at room temperature (23°C) for 20 minutes without heating in a block incubator.

[0091] (Comparative example C6) A 1.5 mL solution was prepared in a tube by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 (corresponding to 50 μg of ellagic acid) with 50 μL of a 50% ethanol aqueous solution (without added extract). The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare ellagic acid-containing powder. Next, 500 μL of DMSO was added to the tube and mixed with the ellagic acid-containing powder to prepare a mixed solution. The mixed solution was then filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition C-C6.

[0092] (Comparative Example D1) A 1.5 mL solution was prepared in a tube by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 (corresponding to 50 μg of ellagic acid) with 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 (corresponding to 500 μg of extract). The solution in the tube was subjected to centrifugation under reduced pressure to remove the solvent and prepare an ellagic acid + extract-containing powder. Next, 500 μL of DMSO was added to the tube and mixed with the ellagic acid + extract-containing powder to prepare a mixed solution. The mixed solution was then filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition C-D1.

[0093] (evaluation) <Measurement of ellagic acid concentration> The ellagic acid concentration of the obtained liquid composition was measured according to the measurement method described above. The results are shown in Table 3.

[0094] [Table 3]

[0095] <Calculation of Solubilization Rate> Using the above results, the solubilization rate of the added ellagic acid in Examples A1 to A4 and Comparative Example A1 was calculated. For the calculation of the solubilization rate, the degree of solubilization when DMSO was used as the solvent was used as the standard. The degree of solubilization when DMSO was used as the solvent was the value obtained by subtracting the ellagic acid concentration of liquid composition C-B2 (21.2 μg / mL) of Comparative Example B2 from the ellagic acid concentration of liquid composition C-D1 of Comparative Example D1 (101.5 μg / mL) (80.3 μg / mL). Specifically, the degree of solubilization of the added ellagic acid that dissolved was calculated by subtracting the ellagic acid concentration obtained in the corresponding example from the ellagic acid concentration obtained in the example or comparative example, and the solubilization rate (%) was calculated by dividing this by the above 80.3 μg / mL and multiplying by 100. Note that Example A1 corresponds to Example B1, Example A2 corresponds to Example B2, Example A3 corresponds to Example B3, Example A4 corresponds to Example B4, and Comparative Example A1 corresponds to Comparative Example B1. The calculated solubilization rates are shown in Table 4.

[0096] [Table 4]

[0097] (Consideration) As shown in Examples A1 to A4, it was confirmed that ellagic acid can be dissolved at a high concentration by adding it to an extract derived from Terminalia catappa plants and heating it. This is presumed to be because the extract derived from Terminalia catappa plants contains a component that solubilizes ellagic acid, and ellagic acid can be solubilized by heating it in the presence of this component.

[0098] [Investigation into improving the solubility of ellagic acid, Part 2] (Example A5) Liquid composition E-A5 was obtained in the same manner as in Example A1, except that the extract-containing solution (10 mg / mL, containing water extract) prepared in Preparation Example 2 above was used.

[0099] (Example A6) Liquid composition E-A6 was obtained in the same manner as in Example A5, except that heating was performed at 121°C using an autoclave instead of heating in a block incubator.

[0100] (Example A7) Liquid composition E-A7 was obtained in the same manner as in Example A1, except that the extract-containing solution (10 mg / mL, containing 100% ethanol extract) prepared in Preparation Example 3 above was used.

[0101] (Example A8) Liquid composition E-A8 was obtained in the same manner as in Example A7, except that heating was performed at 121°C using an autoclave instead of heating in a block incubator.

[0102] (Example B5) Liquid composition E-B5 was obtained in the same manner as in Example B1, except that the extract-containing solution (10 mg / mL, containing water extract) prepared in Preparation Example 2 above was used.

[0103] (Example B6) Liquid composition E-B6 was obtained in the same manner as in Example B5, except that heating was performed at 121°C using an autoclave instead of heating in a block incubator.

[0104] (Example B7) Liquid composition E-B7 was obtained in the same manner as in Example B1, except that the extract-containing solution (10 mg / mL, containing 100% ethanol extract) prepared in Preparation Example 3 above was used.

[0105] (Example B8) Liquid composition E-B8 was obtained in the same manner as in Example B7, except that heating was performed at 121°C using an autoclave instead of heating in a block incubator.

[0106] (Comparative Example E1) Liquid composition C-E1 was obtained in the same manner as in Example A5, except that it was left at room temperature (23°C) for 20 minutes without heating in a block incubator.

[0107] (Comparative example E2) Liquid composition C-E2 was obtained in the same manner as in Example A7, except that it was left at room temperature (23°C) for 20 minutes without heating in a block incubator.

[0108] (Comparative example E3) Liquid composition C-E3 was obtained in the same manner as in Example B5, except that it was left at room temperature (23°C) for 20 minutes without heating in a block incubator.

[0109] (Comparative Example E4) Liquid composition C-E4 was obtained in the same manner as in Example B7, except that it was left at room temperature (23°C) for 20 minutes without heating in a block incubator.

[0110] (Comparative Example F1) Liquid composition C-F1 was obtained in the same manner as in Comparative Example D1, except that the extract-containing solution (10 mg / mL, containing water extract) prepared in Preparation Example 2 above was used.

[0111] (Comparative Example F2) Liquid composition C-F2 was obtained in the same manner as in Comparative Example D1, except that the extract-containing solution (10 mg / mL, containing 100% ethanol extract) prepared in Preparation Example 3 above was used.

[0112] (Comparative Example F3) Liquid composition C-F3 was obtained in the same manner as in Comparative Example B2, except that the extract-containing solution (10 mg / mL, containing water extract) prepared in Preparation Example 2 above was used.

[0113] (Comparative Example F4) Liquid composition C-F4 was obtained in the same manner as in Comparative Example B2, except that the extract-containing solution (10 mg / mL, containing 100% ethanol extract) prepared in Preparation Example 3 above was used.

[0114] (evaluation) <Measurement of ellagic acid concentration> The ellagic acid concentration of the obtained liquid composition was measured according to the measurement method described above. The results are shown in Table 5.

[0115] [Table 5]

[0116] <Calculation of Solubilization Rate> Using the above results, the solubilization rates of the added ellagic acid in Examples A5 to A8 and Comparative Examples E1 to E2 were calculated in the same manner as described above. Note that Example A5 corresponds to Example B5, Example A6 to Example B6, Example A7 to Example B7, Example A8 to Example B8, Comparative Example E1 to Comparative Example E3, and Comparative Example E2 to Comparative Example E4. The degree of solubilization when using DMSO as the solvent, which was used as the standard for calculating the solubilization rates of Examples A5, A6, and Comparative Example E1, was 87.3 μg / mL, obtained by subtracting the ellagic acid concentration of Comparative Example F3 (18.4 μg / mL) from the ellagic acid concentration of Comparative Example F1 (105.7 μg / mL). The degree of solubilization when using DMSO as the solvent, which was used as the standard for calculating the solubilization rates of Examples A7, A8, and Comparative Example E2, was 101.5 μg / mL, obtained by subtracting the ellagic acid concentration of Comparative Example F4 (22.0 μg / mL) from the ellagic acid concentration of Comparative Example F2 (123.5 μg / mL). The calculated solubilization rates are shown in Table 6.

[0117] [Table 6]

[0118] (Consideration) As shown in Examples A5 to A8, the solubilization rate of ellagic acid improved even when extracts were used with water and 100% ethanol. As a result, the solubilization rate of ellagic acid was higher with water than with 100% ethanol.

[0119] [Investigation into improving the solubility of ellagic acid, Part 3] (Example A9) A 1.5 mL solution was prepared in a tube by mixing 50 μL of the ellagic acid-containing solution (1 mg / mL) prepared in Preparation Example 4 (corresponding to 50 μg of ellagic acid) with 50 μL of the extract-containing solution (10 mg / mL, containing 50% ethanol extract) prepared in Preparation Example 1 (corresponding to 500 μg of extract). The solution in the tube was subjected to vacuum centrifugation to remove the solvent and prepare the extract-containing powder. Next, 500 μL of pure water was added to the tube and mixed with the extract-containing powder to prepare a mixed solution. Next, the tube containing the mixed solution was placed in a block incubator and incubated at 95°C for 20 minutes. Next, the incubated mixed solution was left in the ambient environment to return to room temperature (23°C). Next, the mixed solution in the tube was concentrated by vacuum centrifugation until its volume was reduced to approximately 1 / 10. After that, the mixed solution was filtered through a 0.45 μm filter to remove solid matter and obtain liquid composition E-A9.

[0120] (Example A10) Liquid composition E-A10 was obtained in the same manner as in Example A9, except that the extract-containing solution prepared in Preparation Example 2 (containing 10 mg / mL of water extract) was used instead of the extract-containing solution prepared in Preparation Example 1 (containing 10 mg / mL of 50% ethanol extract).

[0121] (evaluation) <Measurement of ellagic acid concentration> The ellagic acid concentration of the obtained liquid composition was measured according to the measurement method described above. The results are shown in Table 7.

[0122] [Table 7]

[0123] (Consideration) As shown in Examples A9 to A10, it was confirmed that a composition containing an extract derived from a heat-treated Terminalia catappa plant can be further concentrated to obtain a composition containing an even higher concentration of ellagic acid. Considering that the solubility of ellagic acid in water is approximately 20 μg / mL, it is understood that the solubilizing effect of heat treatment of the extract derived from Terminalia catappa plants on obtaining ellagic acid is remarkably significant.

[0124] The upper and / or lower limits of the numerical ranges described herein can be arbitrarily combined to define a preferred range. For example, the upper and lower limits of the numerical ranges can be arbitrarily combined to define a preferred range, the upper limits of the numerical ranges can be arbitrarily combined to define a preferred range, and the lower limits of the numerical ranges can be arbitrarily combined to define a preferred range.

[0125] The claims following this disclosure are expressly incorporated herein into this disclosure, and each claim stands independently as a separate embodiment. This disclosure includes all instances in which an independent claim is replaced by its dependent claim. Furthermore, any additional embodiments derived from the independent claims and subsequent dependent claims are also expressly incorporated herein into this specification.

[0126] Those skilled in the art can use the above description to make the most of this disclosure. The claims and embodiments disclosed herein are merely descriptive and illustrative and should be construed as not limiting the scope of this disclosure in any way. With the help of this disclosure, modifications to the details of the embodiments described above can be made without departing from the basic principles of this disclosure. In other words, various modifications and improvements to the embodiments specifically disclosed above are within the scope of this disclosure.

[0127] Although this embodiment has been described in detail above, the specific configuration is not limited to this embodiment, and any design changes that do not depart from the gist of this disclosure are also included in this disclosure.

Claims

1. A step of preparing a solution containing at least water and a raw material derived from a plant of the genus Terminalia catappa that contains ellagic acid, and The process of subjecting the aforementioned solution to heat treatment. A method for producing an ellagic acid-containing composition, including The aforementioned solution further contains ellagic acid added separately from the ellagic acid contained in the raw material derived from the genus Terminalia catappa, The raw material derived from the genus Terminalia catappa is an extract obtained by extracting from at least one material selected from the leaves, fruits, stems, and branches of the genus Terminalia catappa using an extraction medium. A method for producing a substance, wherein the extraction medium is water, ethanol, or a mixed solvent of water and ethanol.

2. The manufacturing method according to claim 1, further comprising the step of performing a hydrolysis treatment to hydrolyze the ellagitannin contained in the raw material to produce further ellagic acid, and then subjecting the solution obtained by the hydrolysis treatment to a heat treatment.

3. The manufacturing method according to claim 2, wherein the hydrolysis treatment is hydrolysis by acid.

4. The manufacturing method according to any one of claims 1 to 3, wherein the plant of the genus Terminalia is Terminalia catappa.

5. The manufacturing method according to any one of claims 1 to 4, wherein the heat treatment temperature is 60°C or higher.

6. The manufacturing method according to any one of claims 1 to 5, wherein the heat treatment temperature is less than 100°C.

7. A manufacturing method according to any one of claims 1 to 6, further comprising a step of concentrating the solution after the step of applying heat treatment.

8. The manufacturing method according to any one of claims 1 to 7, wherein the concentration of ellagic acid dissolved in the solution obtained by the heat treatment step, or, if applicable, the concentration treatment step, is 50 μg / mL or more.

9. A manufacturing method according to any one of claims 1 to 8, further comprising the step of drying the solution after the step of applying heat treatment, or after the step of applying concentration treatment if applicable, to obtain an ellagic acid-containing solid.

10. The use of raw materials derived from plants of the genus Terminalia catappa to solubilize ellagic acid, The raw material derived from the genus Terminalia catappa is an extract obtained by extracting from at least one material selected from the leaves, fruits, stems, and branches of the genus Terminalia catappa using an extraction medium. The extraction medium is water, ethanol, or a mixed solvent of water and ethanol. A solution containing raw materials derived from Terminalia catappa plants and water is heat-treated in the presence of ellagic acid added separately from the ellagic acid contained in the Terminalia catappa plant-derived raw materials.

Images